IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies

Cancer Clinical Trial Compensation: Undue or Long Overdue?

Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

In Brief for June 22, 2022

Journal of Thoracic Oncology Impact Factor Surpasses 20

Step It Up For Research!

Foundation Announces 2022 Young Investigator Grant Recipients

Workshops Offer Opportunities for Education, Networking Based on Shared Interests, Specialties